^
    7ms
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=24, Recruiting, University of Nebraska | N=18 --> 24
    Enrollment change
    |
    temozolomide • abexinostat (CG-781)
    7ms
    Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=15, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    Imbruvica (ibrutinib) • abexinostat (CG-781)
    8ms
    A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) (clinicaltrials.gov)
    P3, N=413, Recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Jun 2025 --> Jun 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    pazopanib • abexinostat (CG-781)
    8ms
    Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov)
    P2, N=170, Recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: May 2025 --> Aug 2027 | Trial primary completion date: Dec 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    abexinostat (CG-781)
    8ms
    FORERUNNER: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=139, Active, not recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Dec 2025 --> Dec 2029 | Trial primary completion date: Dec 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    abexinostat (CG-781)
    8ms
    A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Jun 2024 --> Nov 2025 | Trial primary completion date: Feb 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    abexinostat (CG-781)
    8ms
    A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=87, Active, not recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Sep 2024 --> Oct 2025 | Trial primary completion date: Feb 2024 --> Jan 2025 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    abexinostat (CG-781)
    over1year
    A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Nebraska | Trial completion date: Jun 2027 --> Mar 2027 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion date • Trial primary completion date
    |
    temozolomide • abexinostat (CG-781)
    over1year
    Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma (clinicaltrials.gov)
    P1, N=15, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    Imbruvica (ibrutinib) • abexinostat (CG-781)
    over1year
    Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies (clinicaltrials.gov)
    P1, N=35, Completed, Rahul Aggarwal | Active, not recruiting --> Completed | Phase classification: P1b --> P1
    Trial completion • Phase classification • Combination therapy • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • abexinostat (CG-781)
    almost2years
    A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients (clinicaltrials.gov)
    P1/2, N=12, Active, not recruiting, Xynomic Pharmaceuticals, Inc. | Recruiting --> Active, not recruiting | N=25 --> 12 | Trial completion date: Dec 2023 --> Jun 2024
    Enrollment closed • Enrollment change • Trial completion date
    |
    abexinostat (CG-781)
    almost2years
    FORERUNNER: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (clinicaltrials.gov)
    P2, N=139, Active, not recruiting, Xynomic Pharmaceuticals, Inc. | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    abexinostat (CG-781)